Literature DB >> 30126839

A human cellular noncoding RNA activates the antiviral protein 2'-5'-oligoadenylate synthetase 1.

Brenda M Calderon1,2, Graeme L Conn3.   

Abstract

The 2'-5'-oligoadenylate synthetase (OAS) family of enzymes sense cytosolic dsRNA, a potent signal of viral infection. In response to dsRNA binding, OAS proteins synthesize the second messenger 2'-5'-linked oligoadenylate that activates the latent ribonuclease L (RNase L). RNase L-mediated degradation of viral and cellular RNAs effectively halts viral replication and further stimulates innate immune responses by inducing type I interferon. The OAS/RNase L pathway is therefore central in innate immune recognition and promotion of antiviral host responses. However, the potential for specific RNA sequences or structures to drive OAS1 activation and the molecular mechanisms by which they act are not currently fully understood. Moreover, the cellular regulators of OAS activity are not well defined. Here, we demonstrate that the human cellular noncoding RNA 886 (nc886) activates OAS1 both in vitro and in human A549 cells. We show that a unique structure present only in one of the two structural conformers adopted by nc886 drives potent OAS1 activation. In contrast, the conformer lacking this unique structure activated OAS1 only very weakly. We also found that formation of this OAS1-activating structural motif depends on the nucleotides in the apical-most loop of nc886 and the adjacent helix. These findings identify a cellular RNA capable of activating the OAS/RNase L pathway in human cells and illustrate the importance of structural elements, and their context, in potentiating OAS1 activity.
© 2018 Calderon and Conn.

Entities:  

Keywords:  RNA structure; RNA-binding protein; antiviral defense; double-stranded RNA (dsRNA); innate immunity; nc886; oligoadenylate synthetase; translation regulation

Mesh:

Substances:

Year:  2018        PMID: 30126839      PMCID: PMC6187638          DOI: 10.1074/jbc.RA118.004747

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  47 in total

1.  A cis-acting element in the 3'-untranslated region of human TNF-alpha mRNA renders splicing dependent on the activation of protein kinase PKR.

Authors:  F Osman; N Jarrous; Y Ben-Asouli; R Kaempfer
Journal:  Genes Dev       Date:  1999-12-15       Impact factor: 11.361

2.  Precursor miR-886, a novel noncoding RNA repressed in cancer, associates with PKR and modulates its activity.

Authors:  Kwanbok Lee; Nawapol Kunkeaw; Sung Ho Jeon; Inhan Lee; Betty H Johnson; Gum-Yong Kang; Joo Young Bang; Hyung Soon Park; Chanvit Leelayuwat; Yong Sun Lee
Journal:  RNA       Date:  2011-04-25       Impact factor: 4.942

Review 3.  The oligoadenylate synthetase family: an ancient protein family with multiple antiviral activities.

Authors:  Helle Kristiansen; Hans Henrik Gad; Signe Eskildsen-Larsen; Philippe Despres; Rune Hartmann
Journal:  J Interferon Cytokine Res       Date:  2010-12-12       Impact factor: 2.607

Review 4.  Inhibition of PKR by RNA and DNA viruses.

Authors:  Jeffrey O Langland; Jason M Cameron; Michael C Heck; James K Jancovich; Bertram L Jacobs
Journal:  Virus Res       Date:  2006-05-15       Impact factor: 3.303

5.  2'-5'-Oligoadenylate synthetase is activated by a specific RNA sequence motif.

Authors:  Reinhard Kodym; Elisabeth Kodym; Michael D Story
Journal:  Biochem Biophys Res Commun       Date:  2009-08-05       Impact factor: 3.575

6.  Potential role for snoRNAs in PKR activation during metabolic stress.

Authors:  Osama A Youssef; Sarah A Safran; Takahisa Nakamura; David A Nix; Gökhan S Hotamisligil; Brenda L Bass
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-06       Impact factor: 11.205

7.  Dissection of the adenoviral VA RNAI central domain structure reveals minimum requirements for RNA-mediated inhibition of PKR.

Authors:  Jo L Wilson; Virginia K Vachon; S Sunita; Samantha L Schwartz; Graeme L Conn
Journal:  J Biol Chem       Date:  2014-06-26       Impact factor: 5.157

8.  Human noncoding RNA 886 (nc886) adopts two structurally distinct conformers that are functionally opposing regulators of PKR.

Authors:  Brenda M Calderon; Graeme L Conn
Journal:  RNA       Date:  2017-01-09       Impact factor: 4.942

9.  The ribonuclease L-dependent antiviral roles of human 2',5'-oligoadenylate synthetase family members against hepatitis C virus.

Authors:  Young-Chan Kwon; Ju-Il Kang; Soon B Hwang; Byung-Yoon Ahn
Journal:  FEBS Lett       Date:  2012-11-26       Impact factor: 4.124

10.  Systematic deletion of the adenovirus-associated RNAI terminal stem reveals a surprisingly active RNA inhibitor of double-stranded RNA-activated protein kinase.

Authors:  Ahmed M Wahid; Veronica K Coventry; Graeme L Conn
Journal:  J Biol Chem       Date:  2008-04-22       Impact factor: 5.157

View more
  7 in total

1.  Shapeshifting RNAs guide innate immunity.

Authors:  Jonathan D Dinman
Journal:  J Biol Chem       Date:  2018-10-12       Impact factor: 5.157

Review 2.  RNA regulation of the antiviral protein 2'-5'-oligoadenylate synthetase.

Authors:  Samantha L Schwartz; Graeme L Conn
Journal:  Wiley Interdiscip Rev RNA       Date:  2019-04-15       Impact factor: 9.957

3.  The nuclear and cytoplasmic activities of RNA polymerase III, and an evolving transcriptome for surveillance.

Authors:  Alan C Kessler; Richard J Maraia
Journal:  Nucleic Acids Res       Date:  2021-12-02       Impact factor: 16.971

4.  Noncoding RNA 886 alleviates tumor cellular immunological rejection in host C57BL/C mice.

Authors:  Hui Ma; Miao Wang; Ying Zhou; Jia-Jie Yang; Li-Yong Wang; Rong-Hui Yang; Min-Jie Wen; Lu Kong
Journal:  Cancer Med       Date:  2020-05-31       Impact factor: 4.452

5.  Role of helical structure and dynamics in oligoadenylate synthetase 1 (OAS1) mismatch tolerance and activation by short dsRNAs.

Authors:  Samantha L Schwartz; Debayan Dey; Julia Tanquary; Camden R Bair; Anice C Lowen; Graeme L Conn
Journal:  Proc Natl Acad Sci U S A       Date:  2022-01-18       Impact factor: 12.779

6.  Heterozygous OAS1 gain-of-function variants cause an autoinflammatory immunodeficiency.

Authors:  Thomas Magg; Tsubasa Okano; Lars M Koenig; Daniel F R Boehmer; Samantha L Schwartz; Kento Inoue; Jennifer Heimall; Francesco Licciardi; Julia Ley-Zaporozhan; Ronald M Ferdman; Andrés Caballero-Oteyza; Esther N Park; Brenda M Calderon; Debayan Dey; Hirokazu Kanegane; Kazutoshi Cho; Davide Montin; Karl Reiter; Matthias Griese; Michael H Albert; Meino Rohlfs; Paul Gray; Christoph Walz; Graeme L Conn; Kathleen E Sullivan; Christoph Klein; Tomohiro Morio; Fabian Hauck
Journal:  Sci Immunol       Date:  2021-06-18

7.  Development of Drugs Based on High-Polymeric Double-Stranded RNA for Antiviral and Antitumor Therapy.

Authors:  E D Danilenko; A O Belkina; G M Sysoeva
Journal:  Biochem Mosc Suppl B Biomed Chem       Date:  2019-12-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.